In the presence of an AT1 receptor antagonist, Angiotensin II caused a 29% dilation of preconstricted afferent arterioles, an effect abolished by AT2 receptor blockade or cytochrome P-450 inhibition.
Selective activation of the AT2 receptor causes endothelium-dependent vasodilation in the afferent arteriole via a cytochrome P-450 pathway, likely mediated by epoxyeicosatrienoic acids.
Absolute Event Rate: 29% vs -74%
p-value: p=<0.01
Although angiotensin II type 2 (AT2) receptor has recently been cloned, its functional role is not well understood. We tested the hypothesis that selective activation of AT2 receptor causes vasodilation in the preglomerular afferent arteriole (Af-Art), a vascular segment that accounts for most of the preglomerular resistance. We microperfused rabbit Af-Arts at 60 mmHg in vitro, and examined the effect of angiotensin II (Ang II; 10(-11)-10(-8) M) on the luminal diameter in the presence or absence of the Ang II type 1 receptor antagonist CV11974 (CV; 10(-8) M). Ang II was added to both the bath and lumen of preconstricted Af-Arts. Ang II further constricted Af-Arts without CV (by 74+/-7% over the preconstricted level at 10(-8) M; P < 0.01, n = 7). In contrast, in the presence of CV, Ang II caused dose-dependent dilation; Ang II at 10(-8) M increased the diameter by 29+/-2% (n = 7, P < 0.01). This dilation was completely abolished by pretreatment with an AT2 receptor antagonist PD123319 (10(-7) M, n = 6), suggesting that activation of AT2 receptor causes vasodilation in Af-Arts. The dilation was unaffected by inhibiting either nitric oxide synthase (n = 7) or cyclooxygenase (n = 7), however, it was abolished by either disrupting the endothelium (n = 10) or inhibiting the cytochrome P-450 pathway, particularly the synthesis of epoxyeicosatrienoic acids (EETs, n = 7). These results suggest that in the Af-Art activation of the AT2 receptor may cause endothelium-dependent vasodilation via a cytochrome P-450 pathway, possibly by EETs.
Arima et al. (Mon,) conducted a other in Normal (preclinical animal model). Angiotensin II + CV11974 (AT1 receptor antagonist) vs. Angiotensin II alone was evaluated on Change in luminal diameter of preconstricted afferent arterioles at 10^-8 M Ang II (p=<0.01). In the presence of an AT1 receptor antagonist, Angiotensin II caused a 29% dilation of preconstricted afferent arterioles, an effect abolished by AT2 receptor blockade or cytochrome P-450 inhibition.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: